Oligonucleotide, RNAi, siRNA, Aptamers, Antisense, miRNA AND Peptides for the drug development and manufacturing industry
Key sessions for 2010
EuroTIDES
Hear the latest pre-clinical and clinical updates from; Excaliard, Mirna, miRagen, RXi, NOXXON, Enzon, Topigen, Giuliani, Sylentis, Pro-Cure Therapeutics, Prosensa and Quark
Maximise your time out of the office with a choice of 6 focussed oligos workshops on Analysis, Production, Tools for Start-up, Successful Submission and Out-licensing plus a site visit to the Barcelona Science Park and an Evening seminar on Delivery and Distribution
Case studies on how to reach the maximum therapeutic potential via delivery of oligo-based drugs, from; MDRNA, Ludwig-Maximilians-University, nLife Therapeutics, and Coley Pharmaceutical
Professor Zicai Liang from Peking University will discuss why the development of siRNA based therapeutics have started to gain momentum in China and highlight technology development and capacity build-up
Over 75+ Expert Industry and Academic Speakers
Over 75+ Expert Industry and Academic Speakers
Henrik ØrumVice President & Chief Scientific OfficerSantaris Pharma A/S, Denmark
Michael HanleyChief Scientific OfficerAmylin, USA
John HowlProfessorUniversity of John Howl, UK
Peter NielsenProfessor, Faculty of Health ScienceUniversity of Copenhagen, Denmark
John TolleProgram ManagerAbbott Laboratories, USA
Bruce MorimotoVice President, Drug DevelopmentAllon Therapeutics, USA
Andrea Leone-BayVice President, Pharmaceutical R&DMankinnd, USA
Hüseyin AygünCSOBiospring, Germany
Jamal TemsamaniVice President, Preclinical R&DCLL Pharma, France
Giles CampionChief Medical Officer and Senior Vice-President R&DProsensa Therapeutics, The Netherlands
Robin LeatherbarrowProfessor, Head of Chemical BiologyImperial College London, UK
Maurice ManningProfessorThe University of Toledo, USA
Jesse DongVice President, Compound DiscoveryIpsen, USA
William MarshallPresident and CEOmiRagen, USA
Brian SproatManaging DirectorChemconsilium GCV, Belgium